AI Tokens
Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Adjustments to Financial Statements

Microsoft Excel

Adjustments to Total Assets

Regeneron Pharmaceuticals Inc., adjusted total assets

US$ in thousands

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Total assets 40,558,700 37,759,400 33,080,200 29,214,500 25,434,800
Adjustments
Add: Operating lease right-of-use asset (before adoption of FASB Topic 842)1 — — — — —
Less: Deferred tax assets2 4,077,200 3,314,100 2,575,400 1,723,700 876,900
After Adjustment
Adjusted total assets 36,481,500 34,445,300 30,504,800 27,490,800 24,557,900

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 Operating lease right-of-use asset (before adoption of FASB Topic 842). See details »

2 Deferred tax assets. See details »


Total assets and adjusted total assets both demonstrate a consistent upward trend over the five-year period from 2021 to 2025. However, the magnitude of growth differs between the two figures, indicating systematic adjustments are being made to the reported asset base.

Overall Growth
Total assets increased from US$25.43 billion in 2021 to US$40.56 billion in 2025, representing a cumulative growth of approximately 59.5%. Adjusted total assets grew from US$24.56 billion to US$36.48 billion over the same period, a cumulative increase of roughly 48.5%.
Growth Rate Comparison
The growth rate of total assets consistently exceeds that of adjusted total assets each year. For example, in 2022, total assets grew by 14.8% while adjusted total assets grew by 11.8%. This pattern persists throughout the observed period, suggesting a recurring downward adjustment to the initially reported asset value.
Adjustment Amounts
The difference between total assets and adjusted total assets widens over time. In 2021, the adjustment amounted to US$876.9 million. By 2025, this difference had grown to US$4.08 billion. This increasing disparity suggests the nature or scale of the adjustments is evolving.

The consistent adjustments to total assets warrant further investigation to understand the underlying reasons. Potential causes could include revaluation of assets, write-downs, or corrections of prior-period errors. The increasing magnitude of these adjustments also suggests a need to assess the potential impact on financial reporting and overall financial health.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Adjustments to Current Liabilities

Regeneron Pharmaceuticals Inc., adjusted current liabilities

US$ in thousands

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Current liabilities 4,368,400 3,944,300 3,423,400 3,141,300 3,932,500
Adjustments
Less: Deferred revenue, current portion 553,000 627,700 458,900 477,900 442,000
After Adjustment
Adjusted current liabilities 3,815,400 3,316,600 2,964,500 2,663,400 3,490,500

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


Current liabilities exhibited fluctuations over the five-year period, while adjusted current liabilities demonstrated a similar, though proportionally moderated, pattern. Both metrics increased overall from 2021 to 2025, but not consistently year-over-year.

Overall Trend
Both current liabilities and adjusted current liabilities generally increased between December 31, 2021, and December 31, 2025. Current liabilities grew from US$3,932.5 million to US$4,368.4 million, representing an overall increase of approximately 11.1%. Adjusted current liabilities increased from US$3,490.5 million to US$3,815.4 million, an overall increase of roughly 9.3%.
Year-over-Year Changes
A significant decrease in both current and adjusted current liabilities was observed from 2021 to 2022. Current liabilities fell by approximately 20.1% and adjusted current liabilities decreased by approximately 15.2%. From 2022 to 2023, both metrics experienced increases; current liabilities rose by 8.7% and adjusted current liabilities increased by 11.3%. A further increase occurred from 2023 to 2024, with current liabilities growing by 15.2% and adjusted current liabilities increasing by 11.8%. The rate of increase slowed from 2024 to 2025, with current liabilities growing by 10.7% and adjusted current liabilities increasing by 15.3%.
Relationship Between Metrics
The difference between current liabilities and adjusted current liabilities remained relatively consistent throughout the period. The adjustment consistently reduced the reported current liabilities by approximately US$442.0 million in 2021, US$477.9 million in 2022, US$458.9 million in 2023, US$627.7 million in 2024, and US$553.0 million in 2025. This suggests a systematic adjustment is being applied, potentially related to specific liability classifications or accruals.

The fluctuations suggest potential changes in short-term financing strategies, operational cycles, or the timing of payments. The consistent adjustment indicates a recurring refinement of reported current liabilities, warranting further investigation into the nature of these adjustments.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Adjustments to Total Liabilities

Regeneron Pharmaceuticals Inc., adjusted total liabilities

US$ in thousands

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Total liabilities 9,301,800 8,405,800 7,107,100 6,550,500 6,666,000
Adjustments
Add: Operating lease liability (before adoption of FASB Topic 842)1 — — — — —
Less: Deferred revenue 761,700 813,400 585,600 547,700 515,300
After Adjustment
Adjusted total liabilities 8,540,100 7,592,400 6,521,500 6,002,800 6,150,700

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 Operating lease liability (before adoption of FASB Topic 842). See details »


Total liabilities exhibited an increasing trend over the five-year period, while adjusted total liabilities also increased, though at a generally slower pace. A comparison of the two figures reveals consistent adjustments downward from the reported total liabilities.

Overall Trend
Reported total liabilities increased from US$6,666,000 thousand in 2021 to US$9,301,800 thousand in 2025, representing a cumulative increase of approximately 39.8%. Adjusted total liabilities also increased over the same period, rising from US$6,150,700 thousand to US$8,540,100 thousand, a cumulative increase of roughly 38.9%.
Year-over-Year Changes - Total Liabilities
From 2021 to 2022, total liabilities decreased by approximately 1.6%. A subsequent increase of 8.4% was observed from 2022 to 2023. The largest year-over-year increase occurred between 2023 and 2024, at 18.3%. Growth moderated to 10.8% between 2024 and 2025.
Year-over-Year Changes - Adjusted Total Liabilities
Adjusted total liabilities decreased by 9.8% from 2021 to 2022. An increase of 8.3% was recorded from 2022 to 2023. The period from 2023 to 2024 saw a 16.3% increase, followed by a 12.5% increase from 2024 to 2025.
Adjustment Magnitude
The difference between total liabilities and adjusted total liabilities remained relatively consistent as a percentage of total liabilities. In 2021, the adjustment represented approximately 7.8% of total liabilities. This percentage varied between 7.6% and 8.3% in subsequent years, indicating a stable pattern in the nature of the adjustments being made.

The consistent adjustments suggest the presence of items within the reported total liabilities that are regularly reclassified or revalued. The slower growth rate of adjusted total liabilities compared to total liabilities indicates that these adjustments are mitigating the overall increase in the company’s liability position.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Adjustments to Stockholders’ Equity

Regeneron Pharmaceuticals Inc., adjusted stockholders’ equity

US$ in thousands

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Stockholders’ equity 31,256,900 29,353,600 25,973,100 22,664,000 18,768,800
Adjustments
Less: Net deferred tax assets (liabilities)1 4,077,200 3,314,100 2,575,400 1,723,700 876,900
Add: Deferred revenue 761,700 813,400 585,600 547,700 515,300
After Adjustment
Adjusted stockholders’ equity 27,941,400 26,852,900 23,983,300 21,488,000 18,407,200

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 Net deferred tax assets (liabilities). See details »


Stockholders’ equity exhibited a consistent upward trend from 2021 through 2025. However, adjusted stockholders’ equity reveals a slightly different pattern, indicating potential adjustments impacting the reported equity value. The difference between the two equity figures also demonstrates a trend over the period.

Overall Trend in Stockholders’ Equity
Stockholders’ equity increased from US$18,768.8 million in 2021 to US$31,256.9 million in 2025, representing a cumulative growth of approximately 66.7%. The growth was not linear, with varying increases year-over-year. The largest absolute increase occurred between 2022 and 2023 (US$3,309.1 million), while the smallest occurred between 2024 and 2025 (US$4,403.3 million).
Overall Trend in Adjusted Stockholders’ Equity
Adjusted stockholders’ equity also increased over the five-year period, rising from US$18,407.2 million in 2021 to US$27,941.4 million in 2025. This represents a cumulative growth of approximately 51.8%. Similar to the unadjusted equity, the growth rate varied annually. The largest absolute increase in adjusted equity was observed between 2022 and 2023 (US$2,500.3 million), and the smallest between 2024 and 2025 (US$1,088.5 million).
Difference Between Stockholders’ Equity and Adjusted Stockholders’ Equity
The difference between the two equity figures was US$361.6 million in 2021, increasing to US$3,315.5 million in 2025. This indicates that the magnitude of adjustments to stockholders’ equity is growing over time. The adjustments were US$256.8 million, US$1,176.0 million, US$1,990.8 million, and US$2,500.7 million in 2021, 2022, 2023, and 2024 respectively. This suggests a potential increase in the frequency or size of items requiring adjustment to the reported equity value.

The consistent growth in both stockholders’ equity and adjusted stockholders’ equity suggests overall financial health. However, the widening gap between the two figures warrants further investigation to understand the nature and impact of the adjustments being made.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Adjustments to Capitalization Table

Regeneron Pharmaceuticals Inc., adjusted capitalization table

US$ in thousands

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Finance lease liabilities, current portion — — — — 719,700
Long-term debt 1,985,900 1,984,400 1,982,900 1,981,400 1,980,000
Finance lease liabilities, excluding current portion 720,000 720,000 720,000 720,000 —
Total reported debt 2,705,900 2,704,400 2,702,900 2,701,400 2,699,700
Stockholders’ equity 31,256,900 29,353,600 25,973,100 22,664,000 18,768,800
Total reported capital 33,962,800 32,058,000 28,676,000 25,365,400 21,468,500
Adjustments to Debt
Add: Operating lease liability (before adoption of FASB Topic 842)1 — — — — —
Add: Operating lease liabilities, current (included in Accrued expenses and other current liabilities)2 37,800 30,300 19,000 12,400 12,400
Add: Operating lease liabilities, noncurrent (included in Other noncurrent liabilities)3 229,000 204,100 68,700 55,800 55,800
Adjusted total debt 2,972,700 2,938,800 2,790,600 2,769,600 2,767,900
Adjustments to Equity
Less: Net deferred tax assets (liabilities)4 4,077,200 3,314,100 2,575,400 1,723,700 876,900
Add: Deferred revenue 761,700 813,400 585,600 547,700 515,300
Adjusted stockholders’ equity 27,941,400 26,852,900 23,983,300 21,488,000 18,407,200
After Adjustment
Adjusted total capital 30,914,100 29,791,700 26,773,900 24,257,600 21,175,100

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 Operating lease liability (before adoption of FASB Topic 842). See details »

2 Operating lease liabilities, current (included in Accrued expenses and other current liabilities). See details »

3 Operating lease liabilities, noncurrent (included in Other noncurrent liabilities). See details »

4 Net deferred tax assets (liabilities). See details »


Over the five-year period ending December 31, 2025, both reported and adjusted financial figures demonstrate consistent growth. However, notable differences exist between the reported and adjusted values, particularly concerning debt and stockholders’ equity. The adjusted figures suggest a more conservative capitalization structure than initially reported.

Total Capital
Total reported capital increased steadily from US$21.47 billion in 2021 to US$33.96 billion in 2025, representing a cumulative growth of approximately 58.2%. Adjusted total capital also increased, albeit at a slightly slower pace, moving from US$21.18 billion to US$30.91 billion, a cumulative growth of approximately 46.1%. The divergence between reported and adjusted total capital widens over time, indicating the impact of the adjustments is becoming more substantial.
Debt
Reported total debt remained remarkably stable throughout the period, fluctuating minimally around US$2.70 billion. In contrast, adjusted total debt exhibited a gradual, but consistent, increase from US$2.77 billion in 2021 to US$2.97 billion in 2025. This suggests the adjustments primarily relate to the classification or valuation of debt instruments, resulting in a higher adjusted debt position.
Stockholders’ Equity
Stockholders’ equity experienced substantial growth under both reporting methods. Reported stockholders’ equity rose from US$18.77 billion in 2021 to US$31.26 billion in 2025, a cumulative increase of approximately 66.6%. Adjusted stockholders’ equity also increased, from US$18.41 billion to US$27.94 billion, representing a cumulative increase of approximately 51.7%. The difference between reported and adjusted equity is more pronounced in later years, implying the adjustments reduce the reported equity position.

The consistent growth in both reported and adjusted figures suggests overall financial health. However, the adjustments to debt and equity warrant further investigation. The increasing difference between reported and adjusted values indicates a growing impact from these adjustments, potentially related to changes in accounting treatment or revaluation of assets and liabilities. The relatively stable reported debt, coupled with increasing adjusted debt, suggests a potential reclassification of certain liabilities. Similarly, the lower adjusted equity compared to reported equity could be due to the recognition of previously unrealized losses or the deferral of certain gains.

Capital Structure
The debt-to-equity ratio, calculated using adjusted figures, shows a slight increase over the period. In 2021, adjusted debt represented approximately 13.1% of adjusted capital, while in 2025, it represented approximately 9.6%. This indicates a gradual shift towards a slightly more leveraged capital structure, although the overall leverage remains moderate. The stability of reported debt masks this shift, highlighting the importance of considering the adjusted figures for a more accurate assessment of the company’s financial risk.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Adjustments to Revenues

Regeneron Pharmaceuticals Inc., adjusted revenues

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Revenues 14,342,900 14,202,000 13,117,200 12,172,900 16,071,700
Adjustment
Add: Increase (decrease) in deferred revenue (51,700) 227,800 37,900 32,400 (120,200)
After Adjustment
Adjusted revenues 14,291,200 14,429,800 13,155,100 12,205,300 15,951,500

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


Revenues exhibited volatility over the five-year period. Initial revenues decreased significantly before stabilizing and showing moderate growth. A comparison of reported revenues with adjusted revenues reveals consistent, though relatively small, adjustments downward.

Overall Revenue Trend
Revenues decreased from US$16,071.7 million in 2021 to US$12,172.9 million in 2022, representing a substantial decline. Subsequently, revenues experienced a recovery, increasing to US$13,117.2 million in 2023 and continuing to rise to US$14,202.0 million in 2024. The most recent year, 2025, shows a slight decrease to US$14,342.9 million.
Adjusted Revenue Trend
Adjusted revenues mirrored the trend of reported revenues. A decrease was observed from US$15,951.5 million in 2021 to US$12,205.3 million in 2022. Adjusted revenues then increased to US$13,155.1 million in 2023 and US$14,429.8 million in 2024, before decreasing slightly to US$14,291.2 million in 2025.
Revenue Adjustments
The difference between reported revenues and adjusted revenues remained relatively consistent across all years. In 2021, the adjustment was US$120.2 million. In 2022, the adjustment was US$32.6 million. In 2023, the adjustment was US$42.1 million. In 2024, the adjustment was US$227.8 million. In 2025, the adjustment was US$51.7 million. These adjustments suggest the presence of recurring items impacting reported revenue that are consistently removed for adjusted revenue calculations.

The adjusted revenue figures generally track closely with the reported revenue figures, indicating that the adjustments are not materially altering the overall revenue picture. However, the consistent nature of these adjustments warrants further investigation to understand the underlying causes and their potential impact on future financial performance.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Adjustments to Reported Income

Regeneron Pharmaceuticals Inc., adjusted net income

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Net income 4,504,900 4,412,600 3,953,600 4,338,400 8,075,300
Adjustments
Add: Deferred income tax expense (benefit)1 (785,400) (757,300) (837,800) (746,400) (147,100)
Add: Increase (decrease) in deferred revenue (51,700) 227,800 37,900 32,400 (120,200)
Add: Other comprehensive income (loss), net of tax 85,400 73,000 157,900 (212,600) (55,500)
After Adjustment
Adjusted net income 3,753,200 3,956,100 3,311,600 3,411,800 7,752,500

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 Deferred income tax expense (benefit). See details »


Reported net income exhibited volatility over the five-year period. Initially decreasing from 2021 to 2022, it showed modest recovery in subsequent years, culminating in a slight increase from 2023 to 2024 and 2025. However, adjusted net income demonstrates a different pattern, consistently lower than reported net income each year and displaying a more pronounced downward trend overall.

Net Income Trend
Net income began at US$8,075.3 million in 2021, then decreased significantly to US$4,338.4 million in 2022. A partial recovery occurred in 2023, reaching US$3,953.6 million, followed by a further increase to US$4,412.6 million in 2024. This upward momentum continued modestly into 2025, with net income reaching US$4,504.9 million.
Adjusted Net Income Trend
Adjusted net income started at US$7,752.5 million in 2021, declining to US$3,411.8 million in 2022. This decline continued in 2023, reaching US$3,311.6 million, representing the lowest value in the observed period. A recovery was noted in 2024, with adjusted net income increasing to US$3,956.1 million, but this was followed by a decrease to US$3,753.2 million in 2025.
Relationship Between Reported and Adjusted Net Income
The difference between reported and adjusted net income varied annually. In 2021, the difference was US$322.8 million. This gap widened considerably in 2022 to US$926.6 million, and remained substantial in 2023 at US$642.0 million. The difference narrowed in 2024 to US$456.5 million, but increased again in 2025 to US$751.7 million. This suggests that adjustments consistently reduce reported earnings, and the magnitude of these adjustments has fluctuated over time.

The consistent application of adjustments resulting in lower net income warrants further investigation to understand the nature of these adjustments and their impact on the company’s underlying profitability. The diverging trends between reported and adjusted net income suggest that non-recurring or unusual items are being excluded from the adjusted figures, and their influence on overall financial performance should be assessed.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?